carecentrix

Provider Newsflash February 4, 2021

FDA RECALL

Purpose of this communication:

We are writing to inform you that effective immediately the FDA has issued a notice of a Voluntary recall by Apotex Corp. of 2 batches of Enoxaparin Sodium Injection, USP to the consumer level. This is due to packaging errors resulting in some syringes containing 100 mg/ml concentration having 150 mg/ml markings on the syringe barrel instead of 100 mg/ml markings, and some syringes containing 150 mg/ml concentration having 100 mg/ml markings on the syringe barrel instead of 150 mg/ml markings. Incorrect syringe barrel markings could lead to miscalculation and inaccurate dose administration to patients.

What do I need to do?

- Please review the following recall notice:
- https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/apotex-corp-issues-voluntary-nationwide-recall-enoxaparin-sodium-injection-usp-due-mislabeling?utm_medium=email&utm_source=govdelivery
- Notify impacted patients and facilitate the repair, replacement and/or resolution of the recall, according to the guidelines issued by the manufacturer in the FDA notification.
- Confirm if you have any CareCentrix patients affected by this recall and notify the CareCentrix Quality Department by faxing information– To: 919-792-6718 Attn: Quality Department

Thank you for your prompt attention and cooperation in this matter.